Jeffrey I. Stewart
Advanced in Emphysema

Dr. Jeffrey I. Stewart

Pulmonary Medicine | Intensive Care Medicine
Dartmouth-Hitchcock Clinic
1 Medical Ctr Dr, 
Lebanon, NH 
Accepting New Patients
Advanced in Emphysema
Dartmouth-Hitchcock Clinic
1 Medical Ctr Dr, 
Lebanon, NH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Stewart is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Lebanon, New Hampshire. Dr. Stewart is rated as an Advanced provider by MediFind in the treatment of Emphysema. His top areas of expertise are Pulmonary Hypertension, Acute Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), and Interstitial Lung Disease. Dr. Stewart is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Emphysema.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in PA
Hospital Affiliations
Mary Hitchcock Memorial Hospital
New London Hospital
Mt Ascutney Hospital
Cheshire Medical Center
Central Vermont Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

DARTMOUTH-HITCHCOCK CLINIC
1 Medical Ctr Dr, Lebanon, NH 03756

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-Label Long Term Extension Safety Study
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-Label Long Term Extension Safety Study
Enrollment Status: Completed
Publish Date: August 10, 2022
Intervention Type: Combination product
Study Drug: iNO
Study Phase: Phase 2
View 4 Less Clinical Trials

9 Total Publications

Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study.
Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study.
Journal: Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Published: February 22, 2022
Similar Doctors
Distinguished in Emphysema
Dr. Martin D. Black
Pulmonary Medicine | Intensive Care Medicine
Distinguished in Emphysema
Dr. Martin D. Black
Pulmonary Medicine | Intensive Care Medicine

Concord Hospital Inc

246 Pleasant St, 
Concord, NH 
 (48.5 miles away)
603-224-9661
Languages Spoken:
English
See accepted insurances

Martin Black is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Concord, New Hampshire. Dr. Black is rated as a Distinguished provider by MediFind in the treatment of Emphysema. His top areas of expertise are Emphysema, Lung Metastases, Bullae, Lung Cancer, and Gastrostomy.

Distinguished in Emphysema
Dr. Muhammad F. Mirza
Pulmonary Medicine | Sleep Medicine
Distinguished in Emphysema
Dr. Muhammad F. Mirza
Pulmonary Medicine | Sleep Medicine

Intensive Care Consortium Inc

100 Mcgregor St, 
Manchester, NH 
 (62.0 miles away)
603-668-3545
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Muhammad Mirza is a Pulmonary Medicine specialist and a Sleep Medicine provider in Manchester, New Hampshire. Dr. Mirza is rated as a Distinguished provider by MediFind in the treatment of Emphysema. His top areas of expertise are Emphysema, Bullae, Lung Metastases, and Chronic Obstructive Pulmonary Disease (COPD).

Advanced in Emphysema
Dr. Kamen S. Rangelov
Pulmonary Medicine
Advanced in Emphysema
Dr. Kamen S. Rangelov
Pulmonary Medicine

Concord Hospital-Laconia

80 Highland St, 
Laconia, NH 
 (41.8 miles away)
603-527-4500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kamen Rangelov is a Pulmonary Medicine provider in Laconia, New Hampshire. Dr. Rangelov is rated as a Distinguished provider by MediFind in the treatment of Emphysema. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Asthma, Emphysema, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stewart's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile